Current Report Filing (8-k)
15 Mai 2019 - 11:27PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 15, 2019
Constellation Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-38584
|
|
26-1741721
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
215 First Street, Suite 200
Cambridge, Massachusetts
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
714-0555
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbols(s)
|
|
Name of each exchange on which
registered
|
Common Stock, par value $0.0001
|
|
CNST
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
On May 15, 2019, Abstract #260583,
A Phase 2 Study of
CPI-0610,
a Bromodomain and Extraterminal Protein
Inhibitor (BETi) alone or with Ruxolitinib (RUX), in Patients with Myelofibrosis (MF)
, which had been submitted by Constellation Pharmaceuticals, Inc. to the American Society for Clinical Oncology (ASCO) in connection with the 2019 ASCO Annual
Meeting on May
31-June
4, 2019 in Chicago, Illinois, was published by ASCO. A copy of the abstract is attached hereto as Exhibit 99.1 to this Current Report on
Form 8-K and
is incorporated herein by reference.
The information in this Item 7.01, including
Exhibit 99.1 attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CONSTELLATION PHARMACEUTICALS, INC.
|
|
|
|
|
Date: May 15, 2019
|
|
|
|
By:
|
|
/s/ Jigar Raythatha
|
|
|
|
|
|
|
Name: Jigar Raythatha
Title: Chief Executive
Officer
|
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Constellation Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur Constellation Pharmaceuticals Inc